stockrowKrystal Biotech, Inc.
KRYS Healthcare Biotechnology
Krystal Biotech, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $389.1 million, up 33.9% from fiscal 2024.
- Revenue
- +30.2%
- EPS
- −22.3%
- Free cash flow
- +137.8%
Quarter to September 2026, against a year earlier
Follow KRYS
Alert me
Krystal Biotech, Inc. (KRYS) Net income
Krystal Biotech, Inc.'s net income for fiscal 2025 was $204.8M, up 129.7% from $89.2M in fiscal 2024. Over the twelve months to 30 September 2026 it was $225.2M. Over the past ten years it has ranged from −$140.0M (fiscal 2022) to $204.8M (fiscal 2025) — the current reading is the highest in ten years. Net income has risen for 3 consecutive fiscal years. Krystal Biotech, Inc. ranks 20th of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $204.8M | 129.74% |
| FY2024 | $89.2M | 715.58% |
| FY2023 | $10.9M | — |
| FY2022 | −$140.0M | — |
| FY2021 | −$69.6M | — |
| FY2020 | −$32.2M | — |
| FY2019 | −$19.1M | — |
| FY2018 | −$10.9M | — |
| FY2017 | −$7.9M | — |
| FY2016 | −$1.2M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | $63.1M | 15.15% |
| Jun 2026 | $54.8M | (2.08%) |
| Mar 2026 | $55.9M | 8.82% |
| Dec 2025 | $51.4M | (35.24%) |
| 37 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| TGTX TG Therapeutics, Inc. compare | $441.5M |
| KRYS Krystal Biotech, Inc. | $225.2M |
| CAI Caris Life Sciences,�Inc. compare | $96.1M |
| PTGX Protagonist Therapeutics, Inc. compare | $82.9M |
| TWST Twist Bioscience Corporation compare | −$136.7M |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −$155.5M |
| SYRE Spyre Therapeutics, Inc. compare | −$263.9M |
| CYTK Cytokinetics, Incorporated compare | −$777.9M |
| IBRX ImmunityBio, Inc. compare | −$992.4M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on KRYS
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Altman Z-score
- The full statement